Q3 2022

Source filing unavailable

Q3 2022 · —

Revenue

$0.00

derivedno prior Q3 2021 on file

Net Income

-$713.79K

no prior Q3 2021 on file

EPS Diluted

-$0.17

no prior Q3 2021 on file

Operating Income-$712,642—

Operating Cash Flowderived-$320,211—

Same quarter

no prior Q3 2021 on file

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Lipella Pharmaceuticals Inc. · CIK 1347242 · Engraved from SEC EDGAR